Rectal bleeding and previous anticoagulant treatment in patients with colorectal cancer do not predict outcome

Kirshtein, Boris; Ariad, Samuel; Mizrahi, Shlomo; Man, S.; Walfisch, Shlomo; Perez, Rodrigo Oliva

doi:10.1007/s10151-007-0341-2

Cited by 1 publication

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognoses and survival rates for cancers of the colon differ depending on the localization. The general view is that proximal colon cancer patients have a lower survival rate; however, there are several studies that document no difference in the survival rate for right colon cancer or that demonstrate a better rate [ 8 , 12 , 14 , 20 ]. Benedix et al [ 20 ] reported in their 28,797-patient study that, although the rate of early diagnosis in descending and ascending colon cancers was higher than 50%, the rate was lower in splenic flexura and cecal cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Does Antiaggregant Administration Lead to Early Diagnosis in Proximal Colon Cancer?

Aday

Gündeş

Çiyiltepe

et al. 2017

North Clin Istanbul

View full text Add to dashboard Cite

OBJECTIVE:Cancers of the proximal colon are often diagnosed in advanced stages with iron deficiency anemia and nonspecific symptoms. Aspirin and clopidogrel are commonly used antiaggregant agents for various clinical conditions. The aim of this study was to investigate the effects of antiaggregant medication on the early diagnosis of proximal colon cancer.METHODS:Cases of colon cancer patients who had received curative surgical procedures between January 1, 2013 and July 31, 2016 were retrospectively reviewed. The clinical and pathological results of patients who had used antiaggregant drugs were compared to those who had not.RESULTS:During the studied period, 246 colorectal cancer patients underwent curative surgical procedures. Of the 67 patients with proximal colon cancer who were included in the study, 27 (40.3%) had taken antiaggregant medication. The mean age of the antiaggregant group was 67.1 years (range: 34–88 years), while it was 58.3 years (range: 34–83 years) for the non-antiaggregant group; the difference between the 2 groups was statistically significant (p=0.03). A pathological evaluation revealed that 74.1% of the antiaggregant group was in the early stages (Stage I/II: 7/13), while 42.5% of the non-antiaggregant group was in the early stages (Stage I/II: 2/15); the difference was statistically significant (p=0.011).CONCLUSION:Antiaggregant medication has a positive effect on diagnosing proximal colon cancer at early stages. Patients using aspirin or clopidogrel should undergo a complete colonoscopic evaluation in the presence of gastrointestinal tract bleeding or newly developed anemia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Aspirin and clopidogrel are the antiaggregant agents most frequently administered to patients with, most notably, cardiac pathologies, or to those who have experienced cerebrovascular events or peripheral arterial diseases [ 6 – 8 ]. Gastrointestinal tract bleeding is one of the most significant side effects of antiaggregant use [ 6 , 7 ].…”

mentioning

confidence: 99%

Does Antiaggregant Administration Lead to Early Diagnosis in Proximal Colon Cancer?

Aday

Gündeş

Çiyiltepe

et al. 2017

North Clin Istanbul

View full text Add to dashboard Cite

show abstract

Rectal bleeding and previous anticoagulant treatment in patients with colorectal cancer do not predict outcome

Abstract: Rectal bleeding and anticoagulant treatment do not affect the outcome of newly diagnosed patients with colorectal cancer.

Cited by 1 publication

References 29 publications

Does Antiaggregant Administration Lead to Early Diagnosis in Proximal Colon Cancer?

Does Antiaggregant Administration Lead to Early Diagnosis in Proximal Colon Cancer?

Contact Info

Product

Resources

About